Redmile Group, LLC Uni Qure N.V. Transaction History

Redmile Group, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $8.52 Million - $10.6 Million	-284,160 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $21.8 Million - $31.3 Million	-744,738 Reduced 72.38%	284,160 $9.57 Million
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $3.53 Million - $5.06 Million	-99,929 Reduced 8.85%	1,028,898 $37.2 Million
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $4.26 Million - $5.64 Million	-118,308 Reduced 9.49%	1,128,827 $41.6 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $68.8 Million - $103 Million	-1,526,390 Reduced 55.03%	1,247,135 $56.2 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $8.81 Million - $16.3 Million	220,200 Added 8.62%	2,773,525 $132 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $5.32 Million - $10.7 Million	143,200 Added 5.94%	2,553,325 $183 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $29.2 Million - $56.9 Million	740,600 Added 44.36%	2,410,125 $94.9 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $19.1 Million - $29.8 Million	362,003 Added 27.69%	1,669,525 $130 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $112,299 - $280,481	4,100 Added 0.31%	1,307,522 $78 Million
Q4 2018 Feb 14, 2019	SELL	$22.8 - $33.93 $7.67 Million - $11.4 Million	-336,478 Reduced 20.52%	1,303,422 $37.6 Million
Q3 2018 Nov 14, 2018	BUY	$29.75 - $43.08 $461,125 - $667,740	15,500 Added 0.95%	1,639,900 $59.7 Million
Q2 2018 Aug 14, 2018	BUY	$21.96 - $39.94 $35.7 Million - $64.9 Million	1,624,400 New	1,624,400 $61.4 Million

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $825M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.